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ABSTRACT  
Activation of the innate immune system is commonly associated with depression. Immunomodulatory drugs 
may have efficacy for depressive symptoms that are co-morbidly associated with inflammatory disorders. We 
report a large-scale re-analysis by standardized procedures (mega-analysis) of patient-level data combined 
from 18 randomized clinical trials conducted by Janssen or GlaxoSmithKline for one of nine disorders 
(N=10,743 participants). Core depressive symptoms (low mood, anhedonia) were measured by the Short Form 
Survey (SF-36) or the Hospital Anxiety and Depression Scale (HADS), and participants were stratified into high 
(N=1,921) versus low-depressive strata based on baseline ratings. Placebo-controlled change from baseline 
after 4-16 weeks of treatment was estimated by the standardized mean difference (SMD) over all trials and for 
each subgroup of trials targeting one of 7 mechanisms (IL-6, TNF-α, IL12/23, CD20, COX2, BLγS, 
p38/MAPK14). Patients in the high-depressive stratum showed modest but significant effects on core 
depressive symptoms (SMD=0.29, 95% CI [0.12-0.45]) and related SF-36 measures of mental health and 
vitality. Anti-IL6 antibodies (SMD=0.8, 95% CI [0.20-1.41]) and an anti-IL12/23 antibody (SMD=0.48, 95% CI 
[0.26-0.70]) had larger effects on depressive symptoms than other drug classes. Adjustments for physical 
health outcome marginally attenuated the average treatment effect on depressive symptoms (SMD=0.20, 95% 
CI: 0.06-0.35), but more strongly attenuated effects on mental health and vitality. Effects of anti-IL12/23 
remained significant and anti-IL6 antibodies became a trend after controlling for physical response to 
treatment. Novel immune-therapeutics can produce antidepressant effects in depressed patients with primary 
inflammatory disorders that are not entirely explained by treatment-related changes in physical health. 
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INTRODUCTION  
Activation of the innate immune system is associated with major depressive disorder (MDD). Case-
control studies and meta-analyses have reported that patients have modestly elevated peripheral blood levels 
of pro-inflammatory cytokines and acute phase proteins, including C-reactive protein (CRP)1, 2, tumor necrosis 
factor-alpha (TNF-α)3-5, and interleukin-6 (IL-6)4, 6. Increased cerebrospinal fluid levels of pro-inflammatory 
cytokines have been reported7, 8 and correlated with reduced hippocampal volume in depressed patients9. A 
central pro-inflammatory process has also been indicated by post mortem studies of microglial activation and 
PET studies of TSPO ligand binding in MDD10, 11.  
Clinical evidence for a causal effect of inflammatory challenge on the pathogenesis of depressive 
symptoms includes data from interferon alpha (IFN-α) treatment trials for hepatitis C, which frequently induces 
symptoms of depression and fatigue, with a concomitant increase in inflammatory markers in peripheral 
blood12 and CSF13. In the chronic social defeat stress model in rodents, animals susceptible to developing 
persistent depression-like behaviors manifest higher peripheral blood levels of IL-6 both before and after stress 
exposure14. Susceptibility to developing depressive phenotypes was reduced in IL6-/- animals; but increased in 
wild type animals by transplanting the immune cells of donor animals that had previously expressed a 
depressive response to social stress14.  
To date, only a few studies have addressed the therapeutic hypothesis that anti-inflammatory drugs 
may have anti-depressant efficacy. Infliximab, an anti-TNF-α antibody, was not effective for depressive 
symptoms in subjects with treatment-resistant MDD; but post hoc analysis indicated that the subgroup of 
patients with high CRP was more responsive15. A small molecule inhibitor of P38 MAP kinase was not 
consistently effective in two studies of MDD16. However, there was evidence of a moderate-sized anti-
inflammatory drug effect (SMD=0.34; 95% CI [0.11-0.57]) on depressive symptoms in a meta-analysis of 
clinical trial data on NSAIDs and anti-cytokine antibodies in patients with a primary diagnosis of depression or 
inflammatory disorder17, and in a meta-analysis of anti-cytokine antibody effects on depressive symptoms in 
inflammatory disorders (SMD=0.44; 95% CI [0.22-0.59])4, 18-21.  
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In any analysis of depressive symptom changes during anti-inflammatory drug treatment of an 
inflammatory disorder it is important to control for treatment effects on physical symptoms (e.g., swollen and 
painful joints in rheumatoid arthritis). Anti-inflammatory drug effects on psychological symptoms may arise 
secondarily to treatment effects on the physical signs and symptoms of inflammatory disorders. Alternatively, 
the antidepressant efficacy of anti-inflammatory drugs may reflect a direct, mechanistically related effect of 
treatment. This hypothetical dilemma remains unresolved17, 18.   
Here we report a large, integrated analysis of existing clinical trial datasets to further investigate anti-
inflammatory drug effects on depressive symptoms. Access to patient-level data (N=10,745) enabled us to 
identify the cohort of trial participants with high-depressive symptoms at baseline, to focus on improvement in 
the DSM 5 cardinal depressive symptoms of depressed mood and anhedonia, and to control for physical 
health outcomes (although high depressive patients were not randomly allocated to treatment groups in the 
primary studies). We analyzed 18 double-blind, placebo-controlled, randomized clinical trials, sponsored by 
Janssen or GlaxoSmithKline, of 9 compounds targeting 7 mechanisms of action (TNF-α, IL-12/23, IL6, CD20, 
COX2, BLγS, and P38/MAPK14) in patients with a primary diagnosis of one of 9 inflammatory or oncological 
disorders (see Table 1). 
 
METHODS 
Study inclusion criteria 
Placebo-controlled, double-blind, randomized, parallel group studies, with publically pre-registered 
designs, were included if (1) the drug primarily targeted an immune mechanism of action and (2) depressive 
symptom severity was assessed at baseline and follow-up visits scheduled 4 to 16 weeks post-randomization; 
see Table 1 and Supplementary Table 1 for details.  
Outcome measures 
For all but one trial, the SF-36 Health Survey (version 1.0 or 2.0)22 was used as a patient reported 
outcome (PRO) measure. The SF-36 comprises 36 self-report measures of physical and mental health that 
can be summarized by 8 domain scores and two component scores (physical and mental health). We used the 
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mental health component score and the vitality domain score as standard SF-36 outcomes. Additionally, to 
focus on depressive symptoms, we constructed a depressive symptom summary score (range, 0-100). This 
was based on the two SF-36 questions (“Have you felt downhearted and depressed?” and “Have you felt so 
down in the dumps that nothing could cheer you up?”) that most closely corresponded to core DSM-5 
symptoms of depressed mood and anhedonia; see Supplementary Information. In one study (C0743T09), 
the Hospital Anxiety and Depression Scale (HADS23) was used instead of the SF-36. In an independent study 
where both scales were measured, the HADS-D was significantly correlated with the defined SF-36 depressive 
symptom score (Spearman r =.63, p<0.0001). 
Depressive symptom stratification 
Patients were stratified as belonging to high depressive or low depressive subgroups based on their 
scores on the two SF-36 questions related to depressed mood and anhedonia. A patient was assigned to the 
high depressive stratum if they rated at least one of these two key symptoms as present at least “most of the 
time” in the previous 4 weeks and rated the other symptom as present at least “some of the time”; 
Supplementary Figure 1. In C0743T09, patients were classified as high-depressive if baseline total HADS 
score was ≥ 823. Notably patients with high depressive symptoms were not randomly allocated to treatment in 
any of the studies (Supplementary Table 2), which fundamentally constrains causal interpretation of treatment 
effects on this subgroup of patients. 
Analysis of baseline data and treatment effects 
Treatment effects were estimated using mixed-effect linear models with repeated measures (MMRM). 
MMRMs were chosen for their ability to leverage all available data and to minimize the introduction of biases in 
the context of missing data under the assumption of missing at random24. The extent of missing data for each 
study, due to participant withdrawal, is indicated in Table 1 by the difference between N at baseline and follow-
up assessments. Separate models were fit for patients in high and low depressive symptom strata. Depressive 
symptom score was the primary dependent variable. Treatment, time, and treatment-by-time interaction were 
fixed effects with time modeled as a repeated measure. Participants were treated as random effects in the 
model. For multi-country studies with >35 patients per treatment arm (Table 1), country was included as a 
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covariate. The association of baseline biomarkers with treatment response is shown in Supplementary Table 
3. The effects on antidepressant treatment outcomes of age, body mass index (BMI), sex and corticosteroid 
use were not consistently significant across studies; see Supplementary Table 2 and Supplementary Figure 
2. 
The within-treatment change was estimated by contrasting the least square means of depressive 
symptom score at baseline and first follow-up visits. The drug treatment effect was estimated by contrasting 
the symptom change in the drug treated arm versus the placebo arm. Analyses were performed using SAS 9.2 
and 9.4 (www.sas.com), and R 3.3.0. The statistical framework is described in more detail for the illustrative 
example of a phase 2 trial of sirukumab for RA, C1377T04 (Supplementary Figure 3).  
Adjustment for treatment effects on physical health 
We controlled the estimation of treatment effects on mental health for the effects of treatment on 
physical health in two ways: i) for each study, the severity scale used to measure clinical efficacy for primary 
disease signs and symptoms (e.g., DAS28-CRP in a rheumatoid arthritis trial C1377T04) was added to the 
mixed model as a time-dependent fixed effect; ii) for a subset of 12 studies (delineated in Table 1) that had 
specified a responder/non-responder criterion a priori, we estimated the treatment effect on depressive 
symptoms only in those high depressive patients who were defined as non-responders on the primary 
(physical health) endpoint of the trial. 
Mega-analysis 
For each study, the standardized mean difference (SMD) was estimated by Cohen’s d: the difference in 
least square means between the treatment and placebo arms divided by the pooled standard deviation. This 
unit-less measure can be compared and combined across studies17.  The R package metafor was used for 
analysis and visualization of forest plots. Treatment effects are reported primarily in terms of 95% confidence 
intervals on the mean SMD; if the 95% CI does not include zero, the treatment effect is statistically significant 
with two-tailed P < 0.05.  Heterogeneity across studies was estimated by tau2, I2 and Cochran’s Q statistic (see 
Supplementary Information).   
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RESULTS 
Study characteristics  
The clinical trials included are listed in Table 1. Active treatment groups were defined as patients 
receiving the new immunomodulatory drug at any dose. Treatment and placebo groups may have received 
concomitant medication as detailed in Supplementary Table 1. 
For each study we used self-reported measures of mood and anhedonia at baseline to stratify patients 
into two subgroups, designated as high or low depressive. The proportion of patients belonging to the high 
depressive stratum varied between studies categorized by primary disorder (Table 1; Figure 1A), with the 
greatest proportion of high depressive patients in studies of rheumatoid arthritis (P = 0.004, 2-tailed t-test, 
rheumatoid arthritis vs. all other disorders). Baseline CRP was measured in most studies and the mean 
baseline CRP (averaged across all patients in each study) correlated positively with the proportion of high-
depressive patients (Pearson R2=0.32, P = 0.04, Figure 1B).  
Treatment and placebo effects on core depressive symptoms  
In the high-depressive stratum of patients (N=1,921 over all 18 studies), we estimated the change from 
baseline in depressive symptom severity in each treatment arm (active drug or placebo) in each study. Active 
drug treatment was always associated with significant improvement in depressive symptoms. However, in most 
(17) studies there was also significant improvement in depressive symptoms after treatment with placebo plus 
allowed concomitant medication. The placebo effect size varied widely between studies (Supplementary 
Figure 4), possibly reflecting the heterogeneity of trial designs with respect to the control of concomitant drugs, 
like methotrexate or corticosteroids, that are known to affect mood states, or differences in disease states and 
study populations.  
Over all 18 trials, there was a modest but significant antidepressant effect of immunological treatments 
compared to placebo (SMD=0.29; 95% CI [0.12,0.45]) (Figure 2A).  
To explore the significant heterogeneity of effect sizes related to mechanistic differences between 
drugs, we computed placebo-controlled treatment effects on change from baseline depressive symptom scores 
for each of 7 clusters or classes of studies targeting the same mechanism of action: 5 studies targeted TNFα 
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(3, infliximab; 2, golimumab); 3 targeted BLγS (belimumab); and 2 targeted IL6 (1, sirukumab; 1, siltuximab) 
IL12/23 (ustekinumab), CD20 (ofatumumab), P38/MAPK (losmapimod), or COX-2 (GW406381). The anti-
IL12/23 antibody trial demonstrated significant improvement in depressive symptoms compared to placebo 
(SMD=0.48; 95% CI [0.26, 0.70]). Studies of the two anti-IL-6 antibodies also demonstrated significant anti-
depressant efficacy vs. placebo (SMD=0.80; 95% CI [0.20, 1.41]). There were non-significant trends in favor of 
improved depressive symptoms in patients treated with the anti-BLγS antibody (SMD=0.34; 95%CI [-0.07, 
0.76]), and the two anti-TNFα antibodies (SMD=0.30; 95% CI [-0.08, 0.67]). Studies of the small molecule 
COX-2 inhibitor (GW406381) demonstrated a non-significant trend in favor of improved depressive symptoms 
in patients treated with placebo (SMD=-0.12, 95% CI [-0.34, 0.10]), but it was notable that the change in the 
placebo arm of this study appeared unusually large (Supplementary Figure 4). 
Controlling for treatment effects on physical health outcomes 
First, we included the continuous measure of physical sign and symptom severity measured for each 
study as a covariate in the model used to estimate treatment effects on depressive symptoms (Table 1). After 
this statistical adjustment, anti-depressant effects were somewhat attenuated, but the primary mega-analytic 
estimate of effect size over all studies remained significantly different from zero (SMD=0.20; 95% CI [0.06, 
0.35]). The anti-depressant effect of ustekinumab (targeting IL-12/23) remained significant after correction for 
physical sign and symptom changes (SMD=0.40; 95% CI [0.18, 0.62]); whereas the antidepressant effect of 
drugs targeting IL-6 was attenuated to a non-significant trend (Figure 2B).  
Second, using data from 7 Janssen and 5 GSK studies for which a prior decision rule could be used to 
dichotomize patients as “responders” or “non-responders” with respect to the primary (physical health) 
endpoint of each trial, we estimated treatment effects on depressive symptoms in the non-responder 
subgroups alone. The overall antidepressant effect remained significant (SMD=0.38 95% CI [0.21, 0.55]), with 
significant effects on depressive symptom severity found in non-responders to treatment with anti-TNF-α 
(SMD=0.35; 95% CI [0.09-0.60]) and anti-IL-6 (SMD=0.88; 95% CI [0.16-1.59]) antibodies (Figure 2C). 
Effects of treatment on the SF-36 Mental Health Component Score and the Vitality Domain Score  
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There was a significant effect of anti-inflammatory drug treatment over the 17 studies reporting the SF-
36 for both the mental health component score (SMD=0.28; 95% CI [0.11, 0.44]) and the vitality domain score 
(SMD=0.24; 95% CI [0.09, 0.39]). However, treatment effects on the mental health component score were 
reduced (SMD=0.14; 95% CI [0.02, 0.27]), and the vitality domain score was attenuated to a non-significant 
trend, by statistical control for treatment effects on physical health (Figures 3, 4).  
Sensitivity Analyses. 
There was no significant treatment effect of anti-inflammatory drugs on the depressive symptom 
severity score, the mental health component score, or the vitality domain score, in parallel analyses of SF-36 
data including all subjects, rather than just those with high depressive symptoms (N=10,745 in 18 trials; 
depressive symptom score: SMD=0.00; 95% CI [-0.05, 0.06], see Supplementary Figures 5-7). Additional 
sensitivity analyses were included to assess the effects of the additional covariates of age, gender, and 
corticosteroid use (Supplementary Figure 8 and Supplementary Table 2), and the stringency of the 
definition for the high depressive symptom cohort (Supplementary Figure 2). The effects on the SF-36 
anhedonia and depression items were evaluated separately, and the effect of treatment on depressive 
symptoms among primary disease responders is shown (Supplementary Figure 2). 
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DISCUSSION 
Our principal findings are that depressive symptoms are frequent among patients recruited to clinical 
trials for non-psychiatric inflammatory disorders and that immunomodulatory drug treatment generally causes a 
modest, but significant, improvement in depressive symptoms, specifically in the subgroups of patients with 
high depressive symptoms at baseline (SMD=0.29; 95% CI. 0.12-0.45). These results are compatible with prior 
data implicating inflammation in the pathophysiology and response to treatment of depression1, 2, 25, 26. This 
modest effect size is comparable to meta-analytic estimates of antidepressant efficacy of selective serotonin 
reuptake inhibitors in patients with major depressive disorder27, and comparable to the standardized effect 
sizes seen in meta-analyses of inflammatory cytokines in case-control cohorts1, 4, 6, 28. 
In evaluating these results, it is reasonable to ask how much of the improvement in mental health is 
attributable to treatment benefits for the primary disease states evaluated in these trials. When we controlled 
statistically for treatment effects on physical health, the mega-analytic estimate of anti-depressant effect size 
was reduced (SMD=0.20; 95% CI, 0.06-0.35) but remained significant. Likewise, anti-IL6 and anti-TNF 
antibodies had significant beneficial effects on core depressive symptoms, even in patients who had not 
responded to treatment in terms of improved physical health for the primary disease states studied. In contrast, 
broader measures of mental health or vitality, which included questions probing somatic symptoms, such as 
fatigue, were less robust to statistical correction for physical health outcomes. We conclude that the effects of 
anti-inflammatory drugs on depressive symptoms are not entirely attributable to their effects on physical health. 
However, it may be that somatic symptoms (e.g., fatigue) are more strongly coupled to peripheral tissue 
disease activity than psychological symptoms (e.g., anhedonia). Nevertheless, it is noteworthy that 
conventional assessments of primary disease severity sometimes included a biomarker index of inflammation 
(e.g., the DAS28-CRP index used to assess rheumatoid arthritis severity includes CRP). Adjusting 
antidepressant effects of treatment by DAS28-CRP scores may correct for not only physical health effects of 
treatment but may also attenuate the effect size of any treatment on depressive symptoms or fatigue that are 
mediated by inflammatory mechanisms. 
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The anti-depressant effect size varied between different classes of drug target. Antibodies targeting IL-
6 or IL-12 and IL-23 (IL12/23) had large and statistically significant effect sizes on core depressive symptoms 
before correction for physical health outcomes. Moreover, the antidepressant effect of ustekinumab (anti-
IL12/23 antibody) remained significant after correction for physical health outcome, and the effect of sirukumab 
and siltuximab (anti-IL6 antibodies) remained significant in non-responders for the primary disease states 
evaluated. A variety of evidence implicates IL6 in the pathogenesis of depression9, 29, 30, and a phase 2 trial of 
sirukumab for patients with MDD and CRP > 3 mg/L is currently ongoing (clinicaltrials.gov ID: NCT02473289). 
Increased levels of IL12 in depressed patients were reduced by monoaminergic antidepressant treatment31, 32. 
Antibodies targeting BLγS and TNF-α also demonstrated trend-level efficacy for depressive symptoms. Small 
molecules targeting P38MAPK or COX2 demonstrated the least antidepressant effect which is compatible with 
the lack of compelling evidence for anti-depressant efficacy of these mechanisms in previously published MDD 
trials16. 
The main strength of this study is that we have reported depressive symptom outcomes in 1,921 
patients treated with one of a range of mechanistically selective and innovative drugs in randomized clinical 
trials. Access to patient-level data enabled post hoc patient stratification and statistical controls for physical 
health outcomes, which is not possible in literature-based meta-analyses. The main limitations are related to 
the fact that the primary studies were not prospectively designed to test drug effects on depressive or other 
psychological states. For example, depressive symptoms were usually assessed by the SF-36 questionnaire. 
This PRO measure has the merit of being widely used, allowing consistent evaluation of treatment effects 
across a large number of studies and participants; however, it was not intended to serve as an endpoint for 
anti-depressant efficacy. It is noteworthy, nonetheless, that the depressive symptom score derived from the 
SF-36 is significantly correlated with HADS-D scores. Similarly, the vitality domain score of the SF-36 includes 
questions related to fatigue but it is not designed to test efficacy of anti-inflammatory drugs in treating 
symptoms of fatigue.  
A related issue is that the studies were focused on a diverse range of primary disorders. The 
comparisons between different anti-inflammatory drug effects on depression were not controlled by design for 
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type or severity of physical comorbidity, although we endeavored to mitigate this issue by including physical 
health measures as covariates in the analysis of depressive symptom scores. The primary studies also varied 
in terms of the “standard of care” provided to patients in both placebo and active treatment groups. In 
particular, studies differed in terms of allowed concomitant medications and the percentage of patients using 
corticosteroids. In each study, however, patients in both the placebo and active treatment groups were subject 
to the same standard of care, so this potential between-study difference appeared unlikely to bias within-study 
estimation of treatment effects; furthermore, a post hoc analysis found no significant effect of corticosteroid use 
on between-study variation in treatment effect size (Supplementary Table 2). Likewise, in each study, patients 
were well-matched for age, sex and BMI between treatment groups, suggesting that these factors are unlikely 
to bias estimation of within-study anti-depressant effects. We further evaluated the effect of between-study 
variability in age, sex and BMI and found only a small age effect indicating that older subjects are less 
responsive (Supplementary Figure 2). We were unable to rigorously assess dose-response relationships, 
because most studies used more than one dose of active treatment, but not always the same dose range in 
different studies of the same drug, and data on dose/occupancy relationships were not available for all drugs. 
Finally, patients with high depressive symptoms were not randomly allocated to treatment in any of the studies, 
which fundamentally constrains causal interpretation of treatment effects in this sub-group of treated patients. 
Collectively the limitations of our study highlight the need for future studies designed primarily to 
evaluate the effects of anti-inflammatory drugs on validated efficacy endpoints for depression and fatigue. 
Future studies also are needed to explore whether inflammatory biomarkers at baseline can identify sub-
groups of MDD patients likely to benefit from anti-inflammatory drug treatment. Greater use of predictive 
biomarkers may also be important in managing safety risks by precluding treatment of patients unlikely to 
respond, We note that antidepressants include a black box warning indicating they may increase the risk of 
suicidal thinking in children and adolescents, and that recently the IL-17 inhibitor brodalumab was approved as 
a treatment for psoriasis with a warning that it has been linked to suicidal ideation32. In future trials of 
immunomodulatory drugs for inflammatory disorders associated with high levels of mental health comorbidity, 
such as rheumatoid arthritis, it would be useful to measure outcomes early and frequently to test whether direct 
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effects of treatment on mental health can be demonstrated before treatment effects on physical health are 
evident. 
We conclude that anti-inflammatory drugs can have therapeutic effects on psychological symptoms of 
depression associated with inflammatory disease that are not entirely attributable to treatment effects on 
physical health. Further studies are required to confirm these findings directly. 
 
 
Supplementary information is available at Molecular Psychiatry’s website. 
 
Request for access to the Janssen study data can be submitted through Yale Open Data Access 
[YODA] Project site at http://yoda.yale.edu. Anonymized individual participant data and study documents for 
GSK studies can be requested for further research from www.clinicalstudydatarequest.com. 
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LEGENDS 
Table 1: Characteristics of clinical trials included in the mega-analysis. Placebo-controlled, randomized 
clinical trials of immunomodulatory drugs for treatment of inflammatory or oncological disorders were included 
if SF-36 or HADS data on depressive symptoms were available at baseline and a follow-up visit 4-16 weeks 
after randomization. 
 
Figure 1 High depressive symptoms in clinical trial participants at baseline. A. Left panel, percentage of 
patients meeting criteria for high depressive symptoms at baseline for each trial, grouped by the primary 
disease treated in the study. Abbreviations: rheumatoid arthritis (RA), multicentric Castleman’s disease (MCD). 
Right panel, boxplot indicating significantly higher percentage of patients with high depressive symptoms in RA 
studies compared with other studies combined. The box and whiskers plot indicates median value, interquartile 
range and extreme values. B. Scatterplot of percentage of patients with high depressive symptom scores at 
baseline vs. mean baseline C-reactive protein (CRP). Each point corresponds to a study. 
 
Figure 2: Effects of immunomodulatory drugs (overall and classified by mechanism of action) on 
depressive symptoms in high-depressive stratum of patients. A. Change in depressive symptom scores 
from baseline to follow-up visit was compared between active treatment and placebo arms. The standardized 
mean difference (SMD) is a measure of placebo-controlled anti-depressant effect size that can be compared 
and combined across studies. B. Immunomodulatory drug effects on depressive symptoms were estimated by 
a linear model including the primary disease symptom scale appropriate for each study (Table 1) as a 
covariate to control for drug effects on physical health outcome. C. Immunomodulatory drug effects on 
depressive symptoms were estimated only in the subgroup of high-depressive patients who did not respond 
physically to drug treatment (non-responders).  
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Figure 3: Effects of immunomodulatory drugs (overall and classified by mechanism of action) on SF-36 
Mental Health Component (MC) scores in the high-depressive stratum of patients. A. Change in SF-36 
MC scores from baseline to follow-up visit was compared between active treatment and placebo arms. The 
standardized mean difference (SMD) is a measure of placebo-controlled anti-depressant effect size that can be 
compared and combined across studies. B. Immunomodulatory drug effects on SF-36 MC scores were 
estimated by a linear model including the primary disease symptom scale appropriate for each study (Table 1) 
as a covariate to control for drug effects on physical health outcome.   
 
Figure 4: Effects of immunomodulatory drugs (overall and classified by mechanism of action) on SF-36 
Vitality Domain scores in the high-depressive stratum of patients. A. Change in SF-36 vitality domain 
scores from baseline to follow-up visit was compared between active treatment and placebo arms. The 
standardized mean difference (SMD) is a measure of placebo-controlled anti-depressant effect size that can be 
compared and combined across studies. B. Immunomodulatory drug effects on SF-36 vitality domain scores 
were estimated by a linear model including the primary disease symptom scale appropriate for each study 
(Table 1) as a covariate to control for drug effects on physical health outcome. 
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Table 1:  
 Clinical Trial ID 
 
Study 
Drug 
Number of Subjects
(% high depressive) 
Depressive 
Symptom 
Scale 
Primary
Disease 
Primary Disease 
Symptom  
Scale 
Treatment Arms Follow-
up 
Visit‡ 
 Janssen Trials      
TN
F-
α
 
C0168T37*# Infliximab  358 (20%) SF-36 v1.0 Ulcerative 
Colitis 
MAYO Placebo (119:90) 
5 mg (119:111), 10 mg 
(120:108) 
8 wk
C0168T41*# Infliximab 1025 (23%) SF-36 v1.0 Rheumatoid 
Arthritis 
DAS28-CRP Placebo (345:306) 
 3 mg (341:282), 10 mg 
(339:274) 
6 wk
C0168T44# Infliximab 832 (13%) SF-36 v1.0 Psoriasis PASI Placebo (208:188) 
3 mg (310:302), 5 mg 
(314:306) 
10 wk
C0524T03# Golimumab 303 (10%) SF-36 v1.0 Asthma FEV1 Placebo (77:70) 
50 mg (72:59), 100 mg 
(76:68), 200 mg (78:66) 
12 wk
C0524T09* Golimumab 350 (18%) SF-36 v1.0 Ankylosing 
Spondylitis 
ASAS20 Placebo (76:76) 
50 mg (136:131), 100 mg 
(138:135) 
14 wk
IL
-1
2/
23
 
C0743T08*# Ustekinumab 763 (8%) SF-36 v2.0 Psoriasis PASI Placebo (254:252) 
45 mg (255:255), 90 mg 
(254:248) 
12 wk
C0743T09# Ustekinumab 1219 (27%) HADS Psoriasis PASI Placebo (405:396) 
45 mg (405:401), 90 mg 
(409:404) 
12 wk
IL
-6
 
C1377T04*# Sirukumab 176 (26%) SF-36 v2.0 Rheumatoid 
Arthritis 
DAS28-CRP Placebo (45:40) 
100 mg/2wk (45:44), 25 
mg/4wk (27:27) 
50 mg/4wk (29:27), 100 
mg/4wk (30:28) 
12 wk
MCD2001*# Siltuximab 77 (20%) SF-36 v2.0 Multicentric 
Castleman’s 
Disease 
MCDOS Placebo (26:25) 
11mg/kg /3wk (51:49) 
6 wk
 GlaxoSmithKline Trials      
CD
20
 OFA110634* Ofatumumab 161 (34%) SF-36 v2.0 Rheumatoid 
Arthritis 
DAS28-CRP Placebo (79:65) 
700 mg (82:57) 
16 wk
OFA110635* Ofatumumab 244 (29%) SF-36 v2.0 Rheumatoid 
Arthritis 
DAS28-CRP Placebo (122:112) 
700 mg (122:105) 
16 wk
Co
x2
 
CXA30007 GW406381 1101 (10%) SF-36 v2.0 Osteoarthrit
is-Knee 
WOMAC Placebo (184:133) 
1 mg (186:133), 5 mg 
(186:130), 10 mg 
(184:131), 25 mg 
(179:133), 50 mg 
(181:137) 
12 wk
CXA30009 GW406381 1711 (20%) SF-36 v2.0 Rheumatoid 
Arthritis 
DAS28CRP Placebo (341:245) 
5 mg (348:266), 10 mg 
(348:273), 25 mg 
(344:250), 50 mg 
(330:244) 
12 wk
Bl
γS
 
BEL110751*# Belimumab 812 (16%) SF-36 v2.0 Lupus (SLE) SELENA SLEDAI Placebo (273:246), 1 mg 
(269:248), 10 mg 
(270:252) 
12 wk
BEL110752* Belimumab 860 (17%) SF-36 v2.0 Lupus (SLE) SELENA SLEDAI Placebo (288:277) 
1 mg (285:274), 10 mg 
(287:276) 
12 wk
LBS02*# Belimumab 445 (12%) S-36 v2.0 Lupus (SLE) SELENA SLEDAI Placebo (113:103), 1 mg 
(114:104), 4 mg (111:104), 
10 mg (107:100) 
12 wk
P3
8 
KIP112967 Losmapimod 167 (17%) SF-36 v2.0 Neuropathic 
Pain 
PI-NRS Placebo (80:67), 7.5 mg 
(87:72) 
4 wk
KIP113049 Losmapimod 139 (12%) SF-36 v2.0 Neuropathic 
Pain 
PI-NRS Placebo (71:68), 7.5 mg 
(68:65) 
4 wk
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Annotations: * indicates inclusion in non-responder analysis, # indicates studies with significant treatment effect on primary 
endpoint (physical disease symptom severity scale), ‡follow-up visit indicates the week at which depression improvement was 
assessed in this study, and not the final endpoint for the study. MAYO: Mayo Score for Ulcerative Colitis , DAS28-CRP: Disease 
Activity Score using C-Reactive Protein, PASI: Psoriasis Area Severity Index, FEV1: Forced Expiratory Volume 1, ASAS20: Assessment 
In Ankylosing Spondylitis Response Criteria, MCDOS: Multicentric Castleman’s Disease Overall Score, WOMAC: Western Ontario and 
McMaster Universities Arthritis Index, SELENA SLEDAI: Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) 
modification of the  SLE (Systemic Lupus Erythematosus) Disease Activity Index (SLEDAI) Score, PI-NRS: Pain Intensity Numeric Rating 
Scale. Within the treatment arms column, the number of patients at the baseline line and follow up visits are indicated in 
parenthesis as (Nbaseline:Nfollowup) 
 




